The use of monoclonal antibodies for the treatment of epithelial ovarian cancer (review).

The prognosis for patients with ovarian cancer is still poor and more effective therapeutic modalities are needed. (Radio)immunotherapy using monoclonal antibodies (Mabs) could be one of these approaches. Here, we review the status of (radio)immunotherapy using Mabs for the treatment of ovarian cancer. The Pubmed database was searched for clinical trials investigating the effect of (radio)immunotherapy in ovarian cancer published until October 1, 2007. Keywords for the search were: ovarian cancer, monoclonal antibodies, CA 125, gp38, HER2, HMFG, MUC1, TAG 72 and VEGF. A total of 44 trials on immunotherapy with unconjugated Mabs, Mab vaccination and (radio)immunotherapy directed towards the antigens CA 125, gp38, HER2, MUC1, TAG 72 or VEGF in patients with ovarian cancer were found, reviewed and discussed. Out of these trials, 23 studied immunotherapy with unconjugated Mabs, 5 vaccination with Mabs and 16 trials studied (radio)immunotherapy. The lack of large randomized prospective trials with Mabs directed to tumor-associated antigens expressed on ovarian cancer cells preclude any firm conclusion on the potential of Mabs use in the treatment of ovarian cancer. Oregovomab, directed against CA 125, and bevacizumab, targeting VEGF, are two unconjugated Mabs closest to clinical introduction for the treatment of ovarian cancer. Vaccination with Mab ACA 125 seems promising but these findings need to be confirmed in controlled randomized trials. Sole RIT should be investigated with the appropriate radionuclide and a Mab with high affinity for the specific tumor-associated antigen in the appropriate patient group to determine whether it may have a therapeutic effect. Additionally, appending (radio)immunotherapy with anti-TAG 72 or anti-MUC1 to other treatment strategies such as chemotherapy could also be a strategy worthwhile investigating. The potential of Mabs to complement current treatment paradigms, is encouraging and may bring a significant improvement to the overall therapeutic outcomes currently being achieved in ovarian cancer.

[1]  G. Klee.  Human anti-mouse antibodies. , 2009, Archives of pathology & laboratory medicine.

[2]  R. Burger.  Experience with bevacizumab in the management of epithelial ovarian cancer. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  A. Lopes,et al.  Decreased intraperitoneal disease recurrence in epithelial ovarian cancer patients receiving intraperitoneal consolidation treatment with yttrium‐90‐labeled murine HMFG1 without improvement in overall survival , 2007, International journal of cancer.

[4]  H. Burris,et al.  A phase II trial of EMD72000 (matuzumab), a humanized anti-EGFR monoclonal antibody, in patients with platinum-resistant ovarian and primary peritoneal malignancies. , 2007, Gynecologic oncology.

[5]  B. Monk,et al.  Salvage bevacizumab (rhuMAB VEGF)-based therapy after multiple prior cytotoxic regimens in advanced refractory epithelial ovarian cancer. , 2006, Gynecologic oncology.

[6]  A. Reuss,et al.  The anti-idiotypic antibody abagovomab in patients with recurrent ovarian cancer. A phase I trial of the AGO-OVAR. , 2006, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Molly Brewer,et al.  Clinical activity of pertuzumab (rhuMAb 2C4), a HER dimerization inhibitor, in advanced ovarian cancer: potential predictive relationship with tumor HER2 activation status. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  D. Cohn,et al.  Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. , 2006, Gynecologic oncology.

[9]  D. Mutch,et al.  Bevacizumab combination therapy in recurrent, platinum‐refractory, epithelial ovarian carcinoma , 2006, Cancer.

[10]  R. Burger,et al.  Bevacizumab in patients with advanced platinum-resistant ovarian cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  L. Presta,et al.  Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab , 2006, Cancer Immunology, Immunotherapy.

[12]  K. Lamborn,et al.  Survival benefit associated with human anti-mouse antibody (HAMA) in patients with B-cell malignancies , 2006, Cancer Immunology, Immunotherapy.

[13]  G. Stamp,et al.  Phase III trial of intraperitoneal therapy with yttrium-90-labeled HMFG1 murine monoclonal antibody in patients with epithelial ovarian cancer after a surgically defined complete remission. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  G. Hortobagyi,et al.  Concomitant versus sequential chemotherapy in the treatment of early-stage and metastatic breast cancer. , 2006, Clinical breast cancer.

[15]  A. Iannello,et al.  Role of antibody-dependent cell-mediated cytotoxicity in the efficacy of therapeutic anti-cancer monoclonal antibodies , 2005, Cancer and Metastasis Reviews.

[16]  E. Kimby.  Tolerability and safety of rituximab (MabThera). , 2005, Cancer treatment reviews.

[17]  A. Oza,et al.  Interim report of a phase II clinical trial of bevacizumab (Bev) and low dose metronomic oral cyclophosphamide (mCTX) in recurrent ovarian (OC) and primary peritoneal carcinoma: A California Cancer Consortium Trial , 2005 .

[18]  M. Method,et al.  Final analysis of a randomized dosing study of oregovomab in patients with advanced ovarian cancer , 2005 .

[19]  G. Scambia,et al.  Biological characterization of ovarian cancer: prognostic and therapeutic implications. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[20]  B. Karlan,et al.  Phase I clinical study of pertuzumab, a novel HER dimerization inhibitor, in patients with advanced cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  R. Jain.  Normalization of Tumor Vasculature: An Emerging Concept in Antiangiogenic Therapy , 2005, Science.

[22]  K. Swenerton,et al.  A pilot phase 2 study of oregovomab murine monoclonal antibody to CA125 as an immunotherapeutic agent for recurrent ovarian cancer , 2004, International Journal of Gynecologic Cancer.

[23]  J. Berlin,et al.  Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. , 2004, The New England journal of medicine.

[24]  Steve Nicholson,et al.  A phase I trial of idiotypic vaccination with HMFG1 in ovarian cancer , 2004, Cancer Immunology, Immunotherapy.

[25]  Neal J Meropol,et al.  Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  R. Kreienberg,et al.  Vaccination of Patients with Advanced Ovarian Carcinoma with the Anti-Idiotype ACA125 , 2004, Clinical Cancer Research.

[27]  R. Kreienberg,et al.  Immune responses to murine monoclonal antibody-B43.13 correlate with prolonged survival of women with recurrent ovarian cancer. , 2003, American journal of obstetrics and gynecology.

[28]  G. Denardo,et al.  Human antiglobulin response to foreign antibodies: therapeutic benefit? , 2003, Cancer Immunology, Immunotherapy.

[29]  K. Darcy,et al.  Evaluation of monoclonal humanized anti-HER2 antibody, trastuzumab, in patients with recurrent or refractory ovarian or primary peritoneal carcinoma with overexpression of HER2: a phase II trial of the Gynecologic Oncology Group. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  J. Schlom,et al.  A Phase I study of combined modality (90)Yttrium-CC49 intraperitoneal radioimmunotherapy for ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[31]  P. Kenemans,et al.  Cellular and humoral responses after multiple injections of unconjugated chimeric monoclonal antibody MOv18 in ovarian cancer patients: a pilot study , 2002, Journal of Cancer Research and Clinical Oncology.

[32]  A. de Gramont,et al.  Adoptive immunotherapy of ovarian carcinoma. , 2002, Gynecologic oncology.

[33]  Trisha Gura,et al.  Therapeutic antibodies: Magic bullets hit the target , 2002, Nature.

[34]  D. Goldenberg.  Targeted therapy of cancer with radiolabeled antibodies. , 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  I. Bernstein,et al.  Antibody-directed therapies for hematological malignancies. , 2002, Trends in molecular medicine.

[36]  Rakesh K. Jain,et al.  Normalizing tumor vasculature with anti-angiogenic therapy: A new paradigm for combination therapy , 2001, Nature Medicine.

[37]  J. Schlom,et al.  Intraperitoneal radioimmunochemotherapy of ovarian cancer: a phase I study. , 2001, Cancer biotherapy & radiopharmaceuticals.

[38]  R. Baum,et al.  Induction of CA125-specific B and T cell responses in patients injected with MAb-B43.13--evidence for antibody-mediated antigen-processing and presentation of CA125 in vivo. , 2001, Cancer biotherapy & radiopharmaceuticals.

[39]  P. Kenemans,et al.  Influence of the route of administration on targeting of ovarian cancer with the chimeric monoclonal antibody MOv18: i.v. vs. i.p. , 2001, International journal of cancer.

[40]  M. A. Plaizier,et al.  Radioimmunotherapy with intravenously administered 131I-labeled chimeric monoclonal antibody MOv18 in patients with ovarian cancer. , 2000, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  P. Rouanet,et al.  A phase II study of intraperitoneal radioimmunotherapy with iodine-131-labeled monoclonal antibody OC-125 in patients with residual ovarian carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[42]  L J Kricka,et al.  Human anti-animal antibody interferences in immunological assays. , 1999, Clinical chemistry.

[43]  J. Murray,et al.  Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[44]  S. Canevari,et al.  Level of anti‐mouse‐antibody response induced by bi‐specific monoclonal antibody OC/TR in ovarian‐carcinoma patients is associated with longer survival , 1999, International journal of cancer.

[45]  L. Massuger,et al.  Dosimetric analysis of chimeric monoclonal antibody cMOv18 IgG in ovarian carcinoma patients after intraperitoneal and intravenous administration , 1998, European Journal of Nuclear Medicine.

[46]  R. Baum,et al.  Anti-idiotype induction therapy: anti-CA125 antibodies (Ab3) mediated tumor killing in patients treated with Ovarex mAb B43.13 (Ab1) , 1998, Cancer Immunology, Immunotherapy.

[47]  P. Kenemans,et al.  Escalating protein doses of chimeric monoclonal antibody MOv18 immunoglobulin G in ovarian carcinoma patients: A phase I study , 1997, Cancer.

[48]  C. Lamers,et al.  Local but no systemic immunomodulation by intraperitoneal treatment of advanced ovarian cancer with autologous T lymphocytes re‐targeted by a bi‐specific monoclonal antibody , 1997, International journal of cancer.

[49]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with 177Lu-CC49: a phase I/II study. , 1997, Gynecologic oncology.

[50]  U. Wagner,et al.  Immunological responses to the tumor-associated antigen CA125 in patients with advanced ovarian cancer induced by the murine monoclonal anti-idiotype vaccine ACA125. , 1997, Hybridoma.

[51]  J. Schlom,et al.  Intraperitoneal radioimmunotherapy of ovarian cancer with lutetium-177-CC49. , 1996, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[52]  F. Guadagni,et al.  Systemic administration of recombinant interferon alfa in carcinoma patients upregulates the expression of the carcinoma-associated antigens tumor-associated glycoprotein-72 and carcinoembryonic antigen. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[53]  J. Fagerberg,et al.  Humoral anti-idiotypic and anti-anti-idiotypic immune response in cancer patients treated with monoclonal antibody 17-1A , 1996, Cancer Immunology, Immunotherapy.

[54]  A. Eggermont,et al.  Regression of advanced ovarian carcinoma by intraperitoneal treatment with autologous T lymphocytes retargeted by a bispecific monoclonal antibody. , 1995, Journal of the National Cancer Institute.

[55]  J. Fisher,et al.  Clinical trials of bispecific antibody MDX-210 in women with advanced breast or ovarian cancer that overexpresses HER-2/neu. , 1995, Journal of hematotherapy.

[56]  J. Fisher,et al.  Phase Ia/Ib trial of bispecific antibody MDX-210 in patients with advanced breast or ovarian cancer that overexpresses the proto-oncogene HER-2/neu. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[57]  G. Hör,et al.  Antiidiotype induction therapy: evidence for the induction of immune response through the idiotype network in patients with ovarian cancer after administration of anti-CA125 murine monoclonal antibody B43.13. , 1995, Hybridoma.

[58]  C. Lamers,et al.  Inhibition of bispecific monoclonal antibody (bsAb)‐targeted cytolysis by human anti‐mouse antibodies in ovarian carcinoma patients treated with bsAb‐targeted activated T‐lymphocytes , 1995, International journal of cancer.

[59]  R. Bast,et al.  Pathogenesis of Ovarian Cancers , 1994, The Journal of the Society for Gynecologic Investigation: JSGI.

[60]  A. Epenetos,et al.  Activation of cellular immunity after intracavitary monoclonal antibody therapy of ovarian cancer , 1994, Cancer.

[61]  H. Abderrahim,et al.  Antigen–specific human monoclonal antibodies from mice engineered with human Ig heavy and light chain YACs , 1994, Nature Genetics.

[62]  M. Neuberger,et al.  Antibodies generated from human immunoglobulin miniloci in transgenic mice. , 1994, Nucleic acids research.

[63]  G. Hör,et al.  Activating anti‐idiotypic human anti‐mouse antibodies for immunotherapy of ovarian carcinoma , 1994, Cancer.

[64]  A. Maraveyas,et al.  Pharmacokinetics and toxicity of an yttrium‐90‐citc‐dtpa‐hmfg1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer , 1994 .

[65]  Uwe Wagner.  Antitumor antibodies for immunotherapy of ovarian carcinomas. , 1993, Hybridoma.

[66]  T. Yokota,et al.  Microautoradiographic analysis of the normal organ distribution of radioiodinated single-chain Fv and other immunoglobulin forms. , 1993, Cancer research.

[67]  P. Schneider,et al.  Clinical immunoscintigraphy of recurrent ovarian cancer with indium 111-labeled B72.3 monoclonal antibody. , 1993, Archives of surgery.

[68]  A. Lefvert,et al.  The clinical significance of HAMA in patients treated with mouse monoclonal antibodies , 1992, Cell Biophysics.

[69]  T. Yokota,et al.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms. , 1992, Cancer research.

[70]  V. Zurawski,et al.  Intraperitoneal radioimmunotherapy of refractory ovarian carcinoma utilizing iodine-131-labeled monoclonal antibody OC125. , 1992, Gynecologic oncology.

[71]  J. Wharton,et al.  Clinical pharmacology, metabolism, and tissue distribution of 90Y-labeled monoclonal antibody B72.3 after intraperitoneal administration. , 1991, Journal of the National Cancer Institute.

[72]  C. Kosmas,et al.  Patients receiving murine monoclonal antibody therapy for malignancy develop T cells that proliferate in vitro in response to these antibodies as antigens. , 1991, British Journal of Cancer.

[73]  D. Snook,et al.  Intraperitoneal yttrium-90-labeled monoclonal antibody in ovarian cancer. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[74]  M. Kuroki,et al.  Serological mapping of the TAG-72 tumor-associated antigen using 19 distinct monoclonal antibodies. , 1990, Cancer research.

[75]  C. Kosmas,et al.  The role of humoral and cellular immunity in patients developing human anti-murine immunoglobulin antibody responses after radioimmunotherapy. , 1990, The British journal of cancer. Supplement.

[76]  D. Goeddel,et al.  Vascular endothelial growth factor is a secreted angiogenic mitogen. , 1989, Science.

[77]  G. Fleuren,et al.  Induction of tumor‐cell lysis by bi‐specific monoclonal antibodies recognizing renal‐cell carcinoma and cd3 antigen , 1989, International journal of cancer.

[78]  J. Taylor‐Papadimitriou,et al.  Intracavitary use of two radiolabeled tumor-associated monoclonal antibodies. , 1988, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[79]  M. V. van Kroonenburgh,et al.  Human immunological response to mouse monoclonal antibodies in the treatment or diagnosis of malignant diseases. , 1988, Nuclear medicine communications.

[80]  S. Ménard,et al.  Characterization of human ovarian carcinoma‐associated antigens defined by novel monoclonal antibodies with tumor‐restricted specificity , 1987, International journal of cancer.

[81]  M. Larché,et al.  Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. , 1986, Cancer research.

[82]  M. Slevin,et al.  A prospective study of 123I-labeled monoclonal antibody imaging in ovarian cancer. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[83]  A. Ross,et al.  Anti-idiotypic antibodies bear the internal image of a human tumor antigen. , 1986, Science.

[84]  R. Dillman,et al.  Toxicities and side effects associated with intravenous infusions of murine monoclonal antibodies. , 1986, Journal of biological response modifiers.

[85]  S L Morrison,et al.  Chimeric human antibody molecules: mouse antigen-binding domains with human constant region domains. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[86]  W. Bodmer,et al.  TARGETING OF IODINE-123-LABELLED TUMOUR-ASSOCIATED MONOCLONAL ANTIBODIES TO OVARIAN, BREAST, AND GASTROINTESTINAL TUMOURS , 1982, The Lancet.

[87]  W. Bodmer,et al.  Monoclonal antibodies to epithelium‐specific components of the human milk fat globule membrane: Production and reaction with cells in culture , 1981, International journal of cancer.

[88]  C. Milstein,et al.  Continuous cultures of fused cells secreting antibody of predefined specificity , 1975, Nature.

[89]  A. Maraveyas,et al.  Asbestos fibers in the colonic wall. , 1974, British Journal of Cancer.

[90]  Salvatore Ca,et al.  [Carcinoma of the ovary]. , 1960, Anais brasileiros de ginecologia.

[91]  A. Jemal,et al.  Cancer Statistics, 2007 , 2007, CA: a cancer journal for clinicians.

[92]  D. Fagret,et al.  Prospect for anti-HER2 receptor therapy in breast cancer. , 2006, Anticancer research.

[93]  E. Pujade-Lauraine,et al.  HER-2 overexpression is an independent marker of poor prognosis of advanced primary ovarian carcinoma: a multicenter study of the GINECO group. , 2004, Annals of oncology : official journal of the European Society for Medical Oncology.

[94]  F. Kabbinavar,et al.  Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[95]  R. Bast,et al.  Prevention of ovarian cancer: intraepithelial neoplasia. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[96]  Antonio J. Grillo-López,et al.  Rituximab: ongoing and future clinical development. , 2002, Seminars in oncology.

[97]  A. Epenetos,et al.  Long term survival of patients with advanced ovarian cancer treated with intraperitoneal radioimmunotherapy. , 2000, International journal of gynecological cancer : official journal of the International Gynecological Cancer Society.

[98]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.

[99]  A. Maraveyas,et al.  Radioimmunotherapy after chemotherapy compared to chemotherapy alone in the treatment of advanced ovarian cancer: a matched analysis. , 1998, Oncology reports.

[100]  E. Seregni,et al.  Single-dose intraperitoneal radioimmunotherapy with the murine monoclonal antibody I-131 MOv18: clinical results in patients with minimal residual disease of ovarian cancer. , 1995, European journal of cancer.

[101]  J. Ortman-Nabi,et al.  Diagnosis of breast carcinoma with radiolabeled monoclonal antibodies (MoAbs) to carcinoembryonic antigen (CEA) and human milk fat globulin (HMFG). , 1995, Cancer investigation.

[102]  A. Lobuglio,et al.  Human immune response to monoclonal antibodies. , 1994, Journal of immunotherapy with emphasis on tumor immunology : official journal of the Society for Biological Therapy.

[103]  J. Murray,et al.  Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[104]  M. McKay,et al.  Cancer of the ovary. , 1994, The New England journal of medicine.

[105]  A. Maraveyas,et al.  Pharmacokinetics and toxicity of an yttrium-90-CITC-DTPA-HMFG1 radioimmunoconjugate for intraperitoneal radioimmunotherapy of ovarian cancer. , 1994, Cancer.

[106]  A. Lanzavecchia,et al.  Adoptive immunotherapy of ovarian carcinoma with bs-MAb-targeted lymphocytes: a multicenter study. , 1992, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[107]  P. Oehr,et al.  Immunotherapy of advanced ovarian carcinomas by activation of the idiotypic network. , 1992, Biotechnology therapeutics.

[108]  C. Kosmas,et al.  Radiolabelled monoclonal antibodies in tumour diagnosis and therapy. , 1990, Developments in biological standardization.

[109]  J. Taylor‐Papadimitriou,et al.  Immunoscintigraphy with 131I‐labelled monoclonal antibodies HMFG2 and HMFG1 F(ab')2 versus abdominal CT scan in the detection of residual disease in ovarian cancer patients , 1988, International journal of cancer. Supplement = Journal international du cancer. Supplement.

[110]  N K Jerne,et al.  Towards a network theory of the immune system. , 1973, Annales d'immunologie.

[111]  Immunological Consolidation of Ovarian Carcinoma Recurrences with Monoclonal Anti-Idiotype Antibody ACA125: Immune Responses and Survival in Palliative Treatment 1 , 2022 .